Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
Zacks.com on MSN3d
GSK Meets Study Goal for Co-Administered RSV-Shingles VaccinesData from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback